ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Corgi All World 2x Daily ETF
25.03
+0.2788
1.13%
成交量:
11
成交额:
299
市值:
37.54万
市盈率:
- -
高:
25.03
开:
24.75
低:
25.03
收:
24.75
52周最高:
25.58
52周最低:
20.48
股本:
1.50万
流通股本:
1.50万
量比:
0.03
换手率:
0.07%
股息:
- -
股息率:
- -
净资产收益率:
--
总资产收益率:
--
市净率:
--
市盈率(LYR):
- -
数据加载中...
总览
公司
新闻资讯
公告
创新药突然哑火,什么原因?华宝基金港股通创新药ETF再失半年线,CXO龙头尽墨,机构:四季度继续看好医药
新浪基金
·
1小时前
CXO与创新药协同共振步入收获季,借港股通创新药ETF嘉实一键布局全产业链
新浪基金
·
5小时前
ETF日报:创新药与CXO仍然是当前医药板块景气度最高的两条主线
新浪基金
·
08/20
CXO概念有支撑 凯莱英(06821)涨2.27% 金斯瑞生物科技(01548)涨2.41%
金吾财讯
·
08/19
国产创新药迎三重业绩拐点 CXO龙头利润与订单同步创出历史新高
智通财经
·
08/19
CXO开启主升浪,药明系、金斯瑞、康龙等集体突破!华宝基金港股通医疗ETF创5个月收盘新高,医疗ETF8天7阳
新浪基金
·
08/18
CXO再度爆发,药明康德H股叒新高!华宝基金港股通医疗ETF(159137)上探3.5%,标的指数CXO含量全市场第一
新浪基金
·
08/17
强业绩引爆CXO行情,哪个可投资指数CXO含量最高?
新浪基金
·
08/17
订单饱满结构升级 CXO企业半年度业绩释放回暖信号
智通财经
·
08/15
医药行业的转折时刻到了
虎嗅APP
·
08/13
联想引爆港股硬科技,159131冲高逾4%!CXO卷土重来,华宝基金医疗ETF创6个月新高!
新浪基金
·
08/13
美银证券:中国CXO行业受惠生物科技融资强劲 上调药明康德等目标价
新浪港股
·
08/13
CXO强者恒强!药明康德AH股齐升,皓元医药涨超8%!华宝基金医疗ETF(512170)涨超2%冲击五连阳
新浪基金
·
08/13
医药调研热度超越半导体!创新药回调,华宝基金港股通创新药ETF失守半年线!CXO韧性十足,药明系逆市飘红
新浪基金
·
08/12
港股异动 | CRO概念股继续走高 药明康德司法取得进展 有利于CXO公司在海外争取新的订单
智通财经
·
08/11
冲高回落,CXO狂欢要散场了?
私募排排网
·
08/10
创新药+CXO齐发力,中报验证产业向上大趋势?
新浪基金
·
08/10
AI制药点燃“卖铲人”行情,CXO巨头刷新多项纪录!创新药接棒在即?基金经理最新解读来了!
新浪基金
·
08/10
智通港股早知道 | SK海力士批准54万亿韩元芯片扩产计划 非京籍家庭购房社保个税缴纳年限下调为一年
智通财经
·
08/10
好“药”知时节!8月创新药能否扛大旗?CXO全线爆发,华宝基金港股通医疗ETF放量劲涨5.51%
新浪基金
·
08/09
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/WX/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"WX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","market":"US","secType":"STK","nameCN":"Corgi All World 2x Daily ETF","latestPrice":25.0259,"timestamp":1787342400000,"preClose":24.7471,"halted":0,"volume":11,"delay":0,"changeRate":0.01126596651728891,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"盘前交易","change":0.2788,"latestTime":"08-24 09:15:06 EDT","open":24.7471,"high":25.0259,"low":25.0259,"amount":299,"amplitude":0,"askPrice":48.03,"askSize":100,"bidPrice":9.02,"bidSize":100,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"exchange":"CBOE","adjPreClose":25.0259,"nav":24.75,"aum":371250,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.7471,"preClose":25.0259,"latestTime":"16:10 EDT","volume":4,"amount":100.1036,"timestamp":1787343004531,"change":-0.2788,"changeRate":-0.01114,"amplitude":0},"volumeRatio":0.026353627734979485},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.026353627734979485,"shares":15000,"dividePrice":0,"high":25.0259,"amplitude":0,"preClose":24.7471,"low":25.0259,"week52Low":20.48,"pbRate":"--","week52High":25.58,"institutionHeld":0,"latestPrice":25.0259,"eps":0,"divideRate":0,"volume":11,"delay":0,"ttmEps":0,"open":24.7471,"prevYearClose":24.72,"prevWeekClose":25.0259,"prevMonthClose":23.7081,"prevQuarterClose":23.5672,"fiveDayClose":25.4996,"twentyDayClose":23.1847},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/WX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"WX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"WX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"WX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661275244","title":"创新药突然哑火,什么原因?华宝基金港股通创新药ETF再失半年线,CXO龙头尽墨,机构:四季度继续看好医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275244","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275244?lang=zh_cn&edition=fundamental","pubTime":"2026-08-24 19:48","pubTimestamp":1787572080,"startTime":"0","endTime":"0","summary":"8月24日,港股深度调整,近期热度较高的医药板块同步走低。100%创新药研发标的——港股通创新药ETF华宝日线连阴,收于半年线下方,全天振幅3.44%,成交3.18亿元。值得一提的是,截至上周,159137在CXO带动连续5周收涨。全链布局创新药,关注两大T+0利器:港股通创新药ETF华宝:被动跟踪恒生港股通创新药精选指数,100%布局创新药研发类公司,7成仓位押注研发龙头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-24/doc-inipmnps2837356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","MEDX","09939","159316","06978","159938","WX","BK1161","LNGR","BK1515","IBBQ","BK1574","CXO","FLHK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661922977","title":"CXO与创新药协同共振步入收获季,借港股通创新药ETF嘉实一键布局全产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2661922977","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661922977?lang=zh_cn&edition=fundamental","pubTime":"2026-08-24 16:07","pubTimestamp":1787558820,"startTime":"0","endTime":"0","summary":"多家尚未登陆 A 股的创新药、CXO 龙头汇聚港股市场,普通投资者想要把握这一轮产业机遇,或可锚定覆盖港股创新药全产业链、CXO含量较高的港股通创新药ETF嘉实及其联接基金来一键布局。如果场内投资者想高效把握港股创新药和CXO龙头的高景气,港股通创新药ETF嘉实或更适配,其支持场内T+0交易,投资效率更高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-24/doc-inipkzxs2033792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LNGR","IBBQ","CXO","520970","159992","BK1574","MEDX","06978","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660428206","title":"ETF日报:创新药与CXO仍然是当前医药板块景气度最高的两条主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2660428206","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660428206?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 21:08","pubTimestamp":1787231280,"startTime":"0","endTime":"0","summary":"受该里程碑临床进展催化,隔夜莫德纳股价大涨近180%,直接带动A股、港股创新药及疫苗板块情绪回暖。基本面角度,创新药与CXO仍然是当前医药板块景气度最高的两条主线。创新药与CXO板块景气度有望延续,感兴趣的投资者可关注20CM弹性的创业板医药ETF与科创创新药ETF;一键布局港股创新药与CXO龙头的恒生生物科技ETF;以及聚焦A股疫苗相关龙头的疫苗ETF。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-20/doc-ininynce8002615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","159938","BK4588","MEDX","06978","BK1574","FDN","LNGR","BK4550","BK1161","WX","IBBQ","CXO","09939","159992","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419923","title":"CXO概念有支撑 凯莱英(06821)涨2.27% 金斯瑞生物科技(01548)涨2.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419923","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660419923?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 10:53","pubTimestamp":1787108028,"startTime":"0","endTime":"0","summary":"金吾财讯 | CCXO概念有支撑,凯莱英 涨2.27%、金斯瑞生物科技涨2.41%、百济神州涨0.63%、方达控股涨0.79%、药明生物涨0.04%爱建证券表示,2026年初以来医药板块的持续回调与行业基本面、产业趋势发生背离,近期众多上市公司推出现金回购和增持方案,反映出对产业未来发展的充足信心,CXO、创新药及相关产业链已率先发力反弹,医药板块中长期布局良机已至。同时,该机构看好高景气CXO、器械出海、脑机接口、AI+医疗等投资机会。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988641","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU1242518931.SGD","LU0043850808.USD","LU0359202008.SGD","LU0359201612.USD","LU0181495838.USD","06160","LU1720050803.USD","LU0516422440.USD","LU0320764599.SGD","06821","LU1688375341.USD","LU0052750758.USD","WX","KURE","LU0828237510.HKD","LU0348825331.USD","LU0708995583.HKD","LU0516423091.SGD","LU0128526141.USD","LU1770034418.SGD","LU0417516738.SGD","LU0819121731.USD","CXO","HK0000320223.HKD","LU0140636845.USD","01521","LU0516422366.SGD","LU1969619763.USD","HK0000306685.HKD","LU0417516902.SGD","BK1191","LU1719994722.HKD","BK1588","BK1589","LU0456827905.SGD","LU0572944931.SGD","BK1500","SG9999002463.SGD","BK1576","LU2328871848.SGD","LU0588546209.SGD","LU0228659784.USD","LU0039217434.USD","002821","01548","BK1141","BK1610","LU3063872942.SGD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490014","title":"国产创新药迎三重业绩拐点 CXO龙头利润与订单同步创出历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490014?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 07:25","pubTimestamp":1787095509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MEDX","WX","CXO","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464424","title":"CXO开启主升浪,药明系、金斯瑞、康龙等集体突破!华宝基金港股通医疗ETF创5个月收盘新高,医疗ETF8天7阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464424","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660464424?lang=zh_cn&edition=fundamental","pubTime":"2026-08-18 19:45","pubTimestamp":1787053500,"startTime":"0","endTime":"0","summary":"8月18日,CXO强者恒强,继续领涨医疗板块!场内高CXO含量ETF继续上行,港股通医疗ETF华宝标的指数CXO含量全市场第一,场内价格续涨1.25%创5个月收盘新高!全市场规模最大医疗ETF华宝CXO含量超30%,斩获8天7阳。药明康德半年度净利润历史首次突破百亿元大关,并大幅上调全年指引;康龙化成Q2收入和经调利润分别同比增长19.38%和22.3%;昭衍新药上半年归母净利润同比预增884.9%至1377.4%。其中药明系占比超38%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-18/doc-inintxxh8569801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","159828","CXO","FLHK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660138101","title":"CXO再度爆发,药明康德H股叒新高!华宝基金港股通医疗ETF(159137)上探3.5%,标的指数CXO含量全市场第一","url":"https://stock-news.laohu8.com/highlight/detail?id=2660138101","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660138101?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 11:19","pubTimestamp":1786936740,"startTime":"0","endTime":"0","summary":"8月17日,港股通医疗板块强势反弹,CXO再度领涨,药明康德港股再创历史新高!场内热门ETF方面,可T+0交易的港股通医疗ETF华宝盘中上探3.5%收复5日线!数据显示,其标的指数CXO含量达52.5%,在全市场可投资指数中为最高,其中药明系权重占比超38%,同样高居首位。最新CXO含量达32.82%,其中药明康德(A股)占比13.42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-17/doc-ininqtns0348637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1719994722.HKD","LU1997245177.USD","LU0320764599.SGD","LU1969619763.USD","LU1303224171.USD","BK0216","LU0469268626.HKD","LU0572944931.SGD","IE00BPRC5H50.USD","LU0708995583.HKD","LU0348766576.USD","FLHK","LU2328871848.SGD","IE00B5MMRT66.SGD","LU2488822045.USD","LU2242644610.SGD","159828","BK1583","LU1046422090.SGD","BK1141","BK1576","LU0348767384.USD","LU1934453819.USD","159137","LU0052750758.USD","LU0700851271.USD","CXO","IE00B543WZ88.USD","LU2125910500.SGD","LU1997245094.SGD","02359","LU0456842615.SGD","603259","LU1770034418.SGD","LU1979443071.USD","LU1251922891.USD","LU0327786744.USD","LU1808992512.USD","LU0611395673.USD","LU2495084118.USD","WX","LU2045819591.USD","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810134","title":"强业绩引爆CXO行情,哪个可投资指数CXO含量最高?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810134","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660810134?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 11:03","pubTimestamp":1786935780,"startTime":"0","endTime":"0","summary":"🔥药明康德交出史上最强中报🚀CXO行业景气上行持续验证一键投资CXO,关注T+0利器👇🏻🔥港股通医疗ETF华宝#159137❤️标的指数CXO含量52.5%,全市场第一❗💙其中药明系权重占比超38%🐲投龙头·选华宝⚠️市场有风险,投资须谨慎","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-17/doc-ininqtnu9181150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659612294","title":"订单饱满结构升级 CXO企业半年度业绩释放回暖信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2659612294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659612294?lang=zh_cn&edition=fundamental","pubTime":"2026-08-15 07:30","pubTimestamp":1786750211,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659691001","title":"医药行业的转折时刻到了","url":"https://stock-news.laohu8.com/highlight/detail?id=2659691001","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659691001?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 21:27","pubTimestamp":1786627620,"startTime":"0","endTime":"0","summary":"以日为镜,产业拐点已现复盘全球资本市场,中国医药行业正处在与日本90年代高度相似的十字路口。上世纪80年代末,日本医药行业同样面临\"人口老龄化+医保控费\"的双重压力。但硬币有两面,这个过程反而使日本医药行业获得了新的机会。自此日本医药行业基本面开始从国内控费周期,走向创新和全球化周期。这是中国医药区别于日本、天花板更高的根本所在。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656193644&idx=1&sn=31e46f943a0b4679b80bf093d14a52ce&chksm=67a87e0cebd46e7c844b957a1f14f55a9a5c0f2479a16a54cad7a66703e950939a896e1368f5&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2328871848.SGD","06160","BK1574","LU0588546209.SGD","LU1969619763.USD","LU0228659784.USD","BK1161","MEDX","BK1500","KURE","IBBQ","BK1588","BK1583","LU1770034418.SGD","WX","LU1303224171.USD","LU0307460666.USD","LU1719994722.HKD","BK1515","LNGR","LU0828237510.HKD","06978","09939","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659315910","title":"联想引爆港股硬科技,159131冲高逾4%!CXO卷土重来,华宝基金医疗ETF创6个月新高!","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315910","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315910?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 19:20","pubTimestamp":1786620000,"startTime":"0","endTime":"0","summary":"联想集团炸裂财报催化,同类规模最大、流动性最强*的港股通信息技术ETF华宝场内价格一度冲高逾4%,收涨2.99%强势连阳。CXO卷土重来,全市场规模最大医疗ETF华宝盘中最高涨至2.86%上探创近6个月新高,收涨1.43%豪取五连阳。联想集团飙升19%创新高!值得注意的是,港股通信息技术权重股联想科技一度涨超19%创历史新高。CXO再度领衔,华宝基金医疗ETF逆市创6个月新高!底层资产是港股,高弹性,T+0。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-13/doc-inineqhp9946806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0128522157.USD","LU0052756011.USD","VXUS","HK0000306701.USD","LU0572940350.SGD","LU0791591158.USD","LU0048580855.USD","LU0791590937.USD","IE0032431581.USD","LU0543330483.HKD","LU1046422090.SGD","LNVGY","LU1366334651.USD","BK4588","LU0049112450.USD","HK0000320264.USD","TCHI","LU1267930227.SGD","LU1235295612.USD","HK0000320223.HKD","LU0320764755.SGD","LU0890818403.SGD","LU0029875118.USD","KCAI","LU0672654166.SGD","80992","LU0862451837.USD","LU0370786039.SGD","IE0034224299.USD","BK1526","LU0862451753.SGD","BK1607","IE0003895053.USD","BK1193","00992","BK4585","WX","03441","LU0310800965.SGD","IE00B0JY6N72.USD","CXO","HK0000306685.HKD","159131","LU0572939691.SGD","LU0264606111.USD","LU2242644610.SGD","159828","LU0128525689.USD","LU1366334578.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138517","title":"美银证券:中国CXO行业受惠生物科技融资强劲 上调药明康德等目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138517?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 12:41","pubTimestamp":1786596060,"startTime":"0","endTime":"0","summary":"模拟交易客户端美银证券发布研报称,受惠上半年全球及中国生物科技一级市场融资表现强劲,加上创新药对外授权交易持续活跃,预期研发活动将进一步加快,中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元,药明康德A股目标价由177.8元人民币至210.5元人民币,维持“买入”评级,因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%,经调整纯利预测亦上调介乎3%至7%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-13/doc-inincxku3329313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LFSC","PSCH","02359","IBRN","PSIL","XBIX","MEDI","FHLC","SMCO","SURI","APXH","WX","161027","CXO","IDNA","BMED","603259","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659187744","title":"CXO强者恒强!药明康德AH股齐升,皓元医药涨超8%!华宝基金医疗ETF(512170)涨超2%冲击五连阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2659187744","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659187744?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 11:25","pubTimestamp":1786591500,"startTime":"0","endTime":"0","summary":"8月13日,AH医疗板块迅速反弹。CXO强者恒强,药明康德AH股双双涨逾1%,康龙化成AH股齐升逾4%,A股皓元医药涨超7%。场内高CXO含量ETF同步走走强,CXO含量超50%的港股通医疗ETF华宝涨逾1%。全市场规模最大医疗ETF华宝CXO含量超30%,盘中涨超2%冲击五连阳,成交超4.5亿元。紧跟医疗反攻行情,关注两大“利器”:港股通医疗ETF华宝:最新CXO含量达51.88%,其中药明系权重占比超38%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-13/doc-ininctaw3414344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688131","LU2495084118.USD","WX","LU1251922891.USD","LU2125910500.SGD","603259","BK1576","LU0348766576.USD","LU0320764599.SGD","LU2488822045.USD","LU0348767384.USD","LU1997245094.SGD","LU1303224171.USD","IE00BPRC5H50.USD","512170","LU1808992512.USD","LU0456842615.SGD","LU1997245177.USD","LU2045819591.USD","02359","CXO","LU1046422090.SGD","LU1979443071.USD","LU0700851271.USD","LU0708995583.HKD","LU1719994722.HKD","LU0611395673.USD","LU1997244956.HKD","LU1770034418.SGD","159828","LU2328871848.SGD","IE00B543WZ88.USD","LU1934453819.USD","BK0216","LU0052750758.USD","LU1969619763.USD","IE00B5MMRT66.SGD","LU2242644610.SGD","BK1583","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658288069","title":"医药调研热度超越半导体!创新药回调,华宝基金港股通创新药ETF失守半年线!CXO韧性十足,药明系逆市飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2658288069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658288069?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 11:02","pubTimestamp":1786503720,"startTime":"0","endTime":"0","summary":"业绩兑现叠加AI制药概念加持,CXO韧性十足,药明生物、药明康德、药明合联逆市飘红,金斯瑞生物科技续涨逾1%。港股通创新药龙头股批量飘绿,百济神州跌2%止步6连阳,翰森制药跌逾3%;再鼎医药延续涨势,股价创年内新高。100%创新药研发标的——港股通创新药ETF华宝冲高回落,现跌1%再失半年线。8月以来,创新药及产业链利好密集,“吃药”行情持续上演。同期医药生物行业的市场关注度大幅攀升。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-12/doc-inimzqcp6895872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159316","VGT","SOXY","SOXX","FLHK","IBBQ","MEDX","CWC","06978","SOXS","XSD","NBDS","WX","TECY","SMHX","USD","BK1161","BK1515","CHPY","BK1574","159582","SSG","BK4535","CHPS","PSI","09939","BK4585","SMHU","EIS","SMH","159992","CXO","FWD","LNGR","SOXL","159938","SOXQ","TEKX","MQQQ","FTXL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658096997","title":"港股异动 | CRO概念股继续走高 药明康德司法取得进展 有利于CXO公司在海外争取新的订单","url":"https://stock-news.laohu8.com/highlight/detail?id=2658096997","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658096997?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 11:47","pubTimestamp":1786420064,"startTime":"0","endTime":"0","summary":"消息面上,CRO行业近期迎来多重利好。药明康德司法进展:暂缓美国国防部针对公司的1260H认定执行。药明康德、百济神州等医药行业龙头公布中期业绩大幅增长。药明康德司法进展事件,有利于CXO公司在海外争取新的订单。中国创新药出海持续超预期,充分验证了中国创新药资产的全球竞争力。我们坚定看好创新药产业链的行业前景,建议关注创新药管线有全球竞争力并有大额BD落地或预期的公司、业绩快速增长的CXO公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02359","BK1583","LU2242644610.SGD","WX","LU1303224171.USD","BK4585","06127","BK1576","BK0216","IE00BPRC5H50.USD","KCAI","LU2328871848.SGD","VXUS","LU0708995583.HKD","LU2495084118.USD","LU0700851271.USD","LU1997245094.SGD","LU1969619763.USD","LU0611395673.USD","HK0000306685.HKD","LU0320764599.SGD","HK0000320264.USD","LU1997244956.HKD","LU0052750758.USD","LU1770034418.SGD","603259","LU1719994722.HKD","01548","LU1979443071.USD","LU1997245177.USD","03759","BK4588","LU1808992512.USD","LU1251922891.USD","LU0348767384.USD","LU0456842615.SGD","LU2125910500.SGD","HK0000306701.USD","LU2488822045.USD","BK1141","HK0000320223.HKD","IE00B543WZ88.USD","LU2045819591.USD","LU1046422090.SGD","IE00B5MMRT66.SGD","LU1934453819.USD","LU0348766576.USD","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936871","title":"冲高回落,CXO狂欢要散场了?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936871","media":"私募排排网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936871?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 19:09","pubTimestamp":1786360140,"startTime":"0","endTime":"0","summary":"整个盘面看下来,CXO这条线热度还在,但短期资金明显开始犹豫了。放到整个CXO行业来说,基本面确实也在回暖。因此,全球创新药融资与大药企研发投入是CXO订单和业绩的核心指标。不过值得注意的是,从6月上旬到现在,CXO板块反弹超35%,创新药概念板块也涨了15%多,短期获利盘应该不少,短期可能有颠簸。CXO这出戏,应该还没到散场的时候。笔者结合公募二季度持仓数据,梳理了基金重仓的CXO公司情况,供读者参考。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-10/doc-inimvsvi8100500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658982630","title":"创新药+CXO齐发力,中报验证产业向上大趋势?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658982630","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658982630?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 17:41","pubTimestamp":1786354860,"startTime":"0","endTime":"0","summary":"截至8月7日,已有22家创新药上市公司发布今年上半年业绩相关报告且普遍向好,其中同比增长的有12家,扭亏的有3家,还有1家减亏。截至8月7日,A股CRO板块中已有8家企业披露半年报或业绩预告,其中6家业绩有望实现两位数及以上增长。结合机构研报,本轮创新药及CXO板块业绩显著提速,主要得益于以下四方面因素的共振。2026年上半年,多家创新药企依托大单品实现销售收入持续放量,验证了企业自建商业化体系的能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-10/doc-inimvnpp4945765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","159992","IBBQ","BK1574","BK1161","06978","MEDX","WX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658825039","title":"AI制药点燃“卖铲人”行情,CXO巨头刷新多项纪录!创新药接棒在即?基金经理最新解读来了!","url":"https://stock-news.laohu8.com/highlight/detail?id=2658825039","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658825039?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 17:41","pubTimestamp":1786354860,"startTime":"0","endTime":"0","summary":"8月以来,港股创新药产业链再起攻势,CXO强势领衔!与此同时,公募医药仓位降至5年冰点,低配状态下易引发扩散性行情。】 AI制药关注度升温,CXO或率先受益。港股金斯瑞生物科技的基因合成、定制化蛋白业务受益AI制药需求提升,中报有望上调全年指引。CXO之后,创新药有望接力行情。预计今年随着商业化端和BD端的推动,行业将普遍盈利超预期兑现,叠加Q3、Q4可能的BD,以及与AI相关的合作,后续创新药有望接棒CXO开启新一轮行情。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-10/doc-inimvnpi1271075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","MEDX","ARTY","06978","BK1191","BK1574","LNGR","QTOC","BK1161","WX","VTHR","IBBQ","CXO","AGIX","AIPO","159992","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658064603","title":"智通港股早知道 | SK海力士批准54万亿韩元芯片扩产计划 非京籍家庭购房社保个税缴纳年限下调为一年","url":"https://stock-news.laohu8.com/highlight/detail?id=2658064603","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658064603?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 07:20","pubTimestamp":1786317636,"startTime":"0","endTime":"0","summary":"公司对法院批准公司所申请的初步禁令的裁决表示欢迎。SK海力士批准54万亿韩元芯片扩产计划!调整后,非京籍家庭在全市范围内购买商品住房的社保或个税缴纳年限统一为“1年”,购买商品住房的套数保持不变。《通知》自8日起实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02611","SKHY","IE00BZ08YR35.GBP","BK1147","SKDD","600988","06693","BK1191","BK1116","02889","02480","BK4141","SKHX","IE00BZ08YS42.EUR","SK","SKHZ","BK1544","BK1515","WX","BK1564","IE00BZ08YT58.USD","BK1521","601211","03330","BK1161","01788","SKHYV","BK1589","HK0000165453.HKD","01177","SKUU","BK1198","SKHU","BK1592","HYNX","BK1144","03677","SBHMY","07709"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672913","title":"好“药”知时节!8月创新药能否扛大旗?CXO全线爆发,华宝基金港股通医疗ETF放量劲涨5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672913","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658672913?lang=zh_cn&edition=fundamental","pubTime":"2026-08-09 19:28","pubTimestamp":1786274880,"startTime":"0","endTime":"0","summary":"尾盘阶段,权重股中际旭创突发跳水,收跌逾3.5%,单日振幅超10%。AH近20股涨超10%,药明康德H股新高,华宝基金港股通医疗ETF放量涨5.51%!医药“炸场”,创新药链全线爆发,港股通医疗ETF华宝、港股通创新药ETF华宝、医疗ETF华宝、药ETF华宝等相关ETF批量大涨!CXO龙头集体猛攻,批量涨超10%!港股通医疗ETF华宝放量劲涨5.51%,标的指数近5成仓位布局CXO龙头,其中药明系权重超35%。随着中报季及创新药管线催化预期到来,持续看好医药后市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-09/doc-inimtpwf1700745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159828","FLHK","MEDX","BK1161","LNGR","IBBQ","06978","159992","BK1574","CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}